The Difficult-to-Treat Del 17 P Patient-A Case Report in Chronic Lymphocytic Leukemia

Overview

Journal Medicina (Kaunas)

Publisher MDPI

Specialty General Medicine

Date 2022 Jan 21

PMID 35056341

Authors

Ana-Maria Moldovianu

Ana Manuela Crisan

Zsofia Varady

Daniel Coriu

Affiliations

Soon will be listed here.

Abstract

Chronic lymphocytic leukemia (CLL) treatment strategies have evolved to include mechanism-driven drugs but now raise new questions regarding their optimum timing and sequencing. In high-risk patients, switching from pathway inhibitors to allogeneic stem cell transplantation (allo-HCT) is still a matter of intense debate. We report the case of a CLL patient with 17 p deletion treated with ibrutinib as a bridge to allo-HCT. Early relapse after allo-HCT urged the initiation of salvage therapy, including donor lymphocytes infusions, ibrutinib, and venetoclax. We aim to outline and discuss the potential benefits of novel therapies, the current role of allo-HCT in CLL, drug timing and sequencing, and the unmet need to improve the long-term outcome of high-risk CLL patients.

References

Tam C, Robak T, Ghia P, Kahl B, Walker P, Janowski W . Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion. Haematologica. 2020; 106(9):2354-2363. PMC: 8409041. DOI: 10.3324/haematol.2020.259432. View

Ma S, Seymour J, Brander D, Kipps T, Choi M, Anderson M . Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy. Blood. 2021; 138(10):836-846. PMC: 9710452. DOI: 10.1182/blood.2020009578. View

Khouri I, Bassett R, Poindexter N, OBrien S, Bueso-Ramos C, Hsu Y . Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer. 2011; 117(20):4679-88. PMC: 4371600. DOI: 10.1002/cncr.26091. View

Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour J, Coutre S . Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol. 2018; 36(19):1973-1980. DOI: 10.1200/JCO.2017.76.6840. View

OBrien S, Jones J, Coutre S, Mato A, Hillmen P, Tam C . Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016; 17(10):1409-1418. DOI: 10.1016/S1470-2045(16)30212-1. View

Blanco G, Puiggros A, Baliakas P, Athanasiadou A, Garcia-Malo M, Collado R . Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations. Oncotarget. 2016; 7(49):80916-80924. PMC: 5348364. DOI: 10.18632/oncotarget.13106. View

van Gelder M, de Wreede L, Bornhauser M, Niederwieser D, Karas M, Anderson N . Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016; 52(3):372-380. DOI: 10.1038/bmt.2016.282. View

Sorror M, Storer B, Sandmaier B, Maris M, Shizuru J, Maziarz R . Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008; 26(30):4912-20. PMC: 2652085. DOI: 10.1200/JCO.2007.15.4757. View

Munir T, Brown J, OBrien S, Barrientos J, Barr P, Reddy N . Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019; 94(12):1353-1363. PMC: 6899718. DOI: 10.1002/ajh.25638. View

10.

Brown J, Kim H, Armand P, Cutler C, Fisher D, Ho V . Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia. 2012; 27(2):362-9. PMC: 3519975. DOI: 10.1038/leu.2012.228. View

11.

Kater A, Seymour J, Hillmen P, Eichhorst B, Langerak A, Owen C . Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol. 2018; 37(4):269-277. DOI: 10.1200/JCO.18.01580. View

12.

Byrd J, Wierda W, Schuh A, Devereux S, Chaves J, Brown J . Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2019; 135(15):1204-1213. PMC: 7146022. DOI: 10.1182/blood.2018884940. View

13.

Bloor A, Thomson K, Chowdhry N, Verfuerth S, Ings S, Chakraverty R . High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2007; 14(1):50-8. DOI: 10.1016/j.bbmt.2007.04.013. View

14.

Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Dohner K . Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014; 123(21):3247-54. DOI: 10.1182/blood-2014-01-546150. View

15.

Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J . Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2006; 21(1):12-7. DOI: 10.1038/sj.leu.2404441. View

16.

Davids M, Hallek M, Wierda W, Roberts A, Stilgenbauer S, Jones J . Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clin Cancer Res. 2018; 24(18):4371-4379. DOI: 10.1158/1078-0432.CCR-17-3761. View

17.

Miklos D, Cutler C, Arora M, Waller E, Jagasia M, Pusic I . Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017; 130(21):2243-2250. PMC: 6033048. DOI: 10.1182/blood-2017-07-793786. View

18.

Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L . Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2001; 343(26):1910-6. DOI: 10.1056/NEJM200012283432602. View

19.

OBrien S, Furman R, Coutre S, Flinn I, Burger J, Blum K . Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018; 131(17):1910-1919. PMC: 5921964. DOI: 10.1182/blood-2017-10-810044. View

20.

Yu L, Kim H, Kasar S, Benien P, Du W, Hoang K . Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation. Clin Cancer Res. 2016; 23(3):735-745. PMC: 5467311. DOI: 10.1158/1078-0432.CCR-16-0594. View